Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Non Squamous Lung Cancer × Therapeutics × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Fatigue 3 Breast Neoplasms 3 Prostatic Neoplasms 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Lymphoma, Follicular 2 Lung Neoplasms 2 Keratosis, Actinic 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma, Hepatocellular 2 Vomiting 1 Vaginal Neoplasms 1 Uterine Cervical Neoplasms 1 Stomach Neoplasms 1 Recurrence 1 Primary Myelofibrosis 1 Postoperative Complications 1 Pneumoperitoneum 1 Peritoneal Neoplasms 1 Pdgfra-Associated Chronic Eosinophilic Leukemia 1 Pain 1 Non Squamous Lung Cancer 1 Nausea 1 Myeloproliferative Disorders 1 Multiple Myeloma 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large-Cell, Immunoblastic 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, B-Cell, Marginal Zone 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01154140 2017-11-06

PROFILE 1014

Pfizer

Phase 3 Completed

343 enrolled 31 charts

Non Squamous Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡